Immune Bio的阿尔茨海默氏病药物试验失败,但在一些病人身上显示出好处,而流感药物则显示出希望。 INmune Bio's Alzheimer's drug failed trials but showed benefits in some patients, while a flu drug showed promise.

Immune Bio的阿尔茨海默氏病药物XPro(XPro)在第二阶段试验失败,导致其库存下降60%。 INmune Bio's Alzheimer's drug, XPro, failed its Phase 2 trial, leading to a 60% drop in its stock. 虽然它没有改善整个认知功能, 但药物展示了好处 在一组病人中 带有特定的炎症标记。 While it didn't improve cognitive functions overall, the drug showed benefits in a subgroup of patients with specific inflammation markers. 同时,Cidara治疗学的预防流感药物CD388在第二阶段b试验中显示出有希望的结果,在一项全球研究中显著减少了类似流感的症状。 Meanwhile, a flu prevention drug, CD388, by Cidara Therapeutics showed promising results in a Phase 2b trial, reducing flu-like symptoms significantly in a global study.